# EDG-7500 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/edg-7500

> The next catalyst for EDG-7500, sponsored by Edgewise Therapeutics, Inc. (EWTX), is its primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | EDG-7500 |
| Codes | EDG-7500 |
| Sponsor | Edgewise Therapeutics, Inc. (EWTX) https://sec-api.dev/companies/ewtx/catalysts |
| Indications | [ohcm](https://sec-api.dev/indications/ohcm), obstructive hcm demonstrated robust reductions in left ventricular outflow tract gradient, ohcm or nhcm, obstructive or nonobstructive hcm, [Hypertrophic Cardiomyopathy](https://sec-api.dev/indications/hypertrophic-cardiomyopathy) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 19, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: oHCM.
- First seen 2025-03-03, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001104659-26-122653): "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM, and on June 16, 2026, we announced positive topline results from Part D of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-091670): "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM, and on June 16, 2026, we announced positive topline results from Part D of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." https://www.sec.gov/Archives/edgar/data/1710072/000110465926091670/ewtx-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056713): "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on April 2, 2025, we announced positive topline" https://www.sec.gov/Archives/edgar/data/1710072/000110465926056713/ewtx-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-020112): "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM, and on December 24, 2025, we announced favorable interim safety results from Part D of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." https://www.sec.gov/Archives/edgar/data/1710072/000110465926020112/ewtx-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-107427): "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and, on April 2, 2025, we" https://www.sec.gov/Archives/edgar/data/1710072/000110465925107427/ewtx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010655): "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." https://www.sec.gov/Archives/edgar/data/1710072/000155837025010655/ewtx-20250630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045896): "In September 2024, the Company announced positive top-line data from Part A of the trial showing that a single oral dose of EDG-7500 in participants with obstructive HCM demonstrated robust reductions in left ventricular outflow tract gradient (LVOT-G) without meaningful changes in left ventricular ejection fraction (LVEF)." https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-030839): "In September 2024, the Company announced positive top-line data from Part A of the trial showing that a single oral dose of EDG-7500 in participants with obstructive HCM demonstrated robust reductions in left ventricular outflow tract gradient ("LVOT-G") without meaningful changes in left ventricular ejection fraction ("LVEF")." https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-019498): "In September 2024, the Company announced positive topline data from Part A showing that treatment with EDG-7500 led to robust left ventricular outflow tract gradient reductions without meaningful changes in left ventricle ejection fraction." https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-25-031266): "In September 2024, we announced positive top-line data from Part A of the trial showing that a single oral dose of" https://www.sec.gov/Archives/edgar/data/1710072/000110465925031266/tm2510462d2_424b5.htm

### Dec 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-03, last confirmed 2025-03-03.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-019498): "In December 2024, the Company announced positive topline results from CANYON, the largest interventional Becker trial that evaluated" https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_ex99-1.htm

### April 2, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-03-03, last confirmed 2025-05-08.
- SEC Form 8-K (accession 0001104659-25-030839): "On April 2, 2025, the Company announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM." https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm
- SEC prospectus (424B) (accession 0001104659-25-031266): "On April 2, 2025, we announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with oHCM or nHCM." https://www.sec.gov/Archives/edgar/data/1710072/000110465925031266/tm2510462d2_424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-019498): "The Company expects to report topline CIRRUS-HCM 28-day data in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045896): "In April 2025, the Company announced positive top-line data from Parts B and C. EDG-7500 over four weeks demonstrated rapid and sustained clinically meaningful reductions in LVOT-G. Further, four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function (Kansas City Cardiomyopathy Questionnaire and/or New York Heart Association functional class scores), reductions in NT-proBNP, a key biomarker of heart failure, and positive trends in measures of diastolic function." https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-030839): "Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of" https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_ex99-1.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-04-02, last confirmed 2025-04-02.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-030839): "The initial data read-out from Part D is expected in the second half of 2025, with Phase 3 initiation planned for the first half of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_ex99-1.htm

### Jun 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001104659-26-122653): "In June 2026, we announced positive topline data for our multipart Phase 2 trial with EDG-7500 for people with HCM (CIRRUS-HCM) and are planning to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm

### Aug 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122654): "In August 2026, the Company shared positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM open label trial of EDG-7500 in obstructive and nonobstructive HCM in a late-breaking science presentation at the European Society of Cardiology Congress, which can be found here." https://www.sec.gov/Archives/edgar/data/1710072/000110465926122654/tm2628556d1_ex99-1.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-07-13, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-082902): "CIRRUS-HCM Phase 2 trial of EDG-7500, which included safety, echocardiographic, biomarker, and patient-reported outcome assessments across both oHCM and nHCM, the Company is expecting to initiate a Phase 3 trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/tm2620181d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122654): ""In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465926122654/tm2628556d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-122653): "In June 2026, we announced positive topline data for our multipart Phase 2 trial with EDG-7500 for people with HCM (CIRRUS-HCM) and are planning to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-122653): "For example, we plan to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026 in the U.S. and in certain countries in Europe, Latin America, Australasia, and Asia." https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-091670): "For example, we plan to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026 in the U.S. and in certain countries in Europe, Latin America, Australasia, and Asia." https://www.sec.gov/Archives/edgar/data/1710072/000110465926091670/ewtx-20260630x10q.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hypertrophic Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06347159 (A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06347159

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hypertrophic Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06347159 (A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06347159

## Same indication

- [MYQORZO® (aficamten)](https://sec-api.dev/pdufa/aficamten) (CYTK)
- [Camzyos® (mavacamten)](https://sec-api.dev/pdufa/mavacamten) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/edg-7500.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EDG-7500 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/edg-7500

```bibtex
@misc{secapidev_pdufa_edg_7500_20261116,
  title        = {EDG-7500 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/edg-7500}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_edg_7500_20261116","title":"EDG-7500 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/edg-7500","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
